Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 15, Issue 3, Pages 127-128Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2018.11
Keywords
-
Categories
Ask authors/readers for more resources
In 2017, FDA Oncology approved 17 new drug and biologic applications, 32 supplemental drug and biologic applications, and two biosimilar applications in oncology. These actions included landmark approvals of two chimeric antigen receptor T cell therapies and the first site-agnostic, biomarker-defined approval. Three next-generation sequencing 'oncopanels' designed to detect hundreds of somatic genetic aberrations were also approved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available